Sznajd J, Idzior-Waluś B, Korzus G, Zabiński J, Hebda A, Markiewicz M
Klinika Chorób Metabolicznych KDB AM w Krakowie.
Przegl Lek. 1990;47(10):711-4.
After three months of beclobrate treatment (100 mg once daily) of 63 patients with primary hyperlipoproteinemia (HLP) significant decrease of total cholesterol concentration was found in type IIa by 12.9%, IIb by 23.7%, IV by 20.8%. LDL cholesterol concentration decreased in type IIa by 15.4%, IIb by 8.3%, in type IV non significant increase of LDL cholesterol by 21.6% was observed. Decrease of initial triglyceride level in type IIa by 36.1%, IIb by 41.2%, in type IV by 56.6% was found. HDL-cholesterol concentration increased in all examined HLP types in IIa by 19.5%, IIb by 19.3%, IV by 14.5%. Also initial apolipoprotein A1 and A2 levels increased in all HLP types examined, namely in type IIa respectively by 21.2% and 12.4%, IIb by 25.1% and 11.0%, in type IV by 23.6% and 34.9%. Serum apolipoprotein B concentration decreased significantly in type IIa by 20.5%, IIb by 28.4%, however in type IV a slight increase of apoprotein B level was observed. Comparison of HLP types response to beclobrate treatment revealed that the HLP types examined are significantly different in change size of LDL cholesterol concentration, triglyceride concentration and apoprotein B concentration after treatment.
对63例原发性高脂蛋白血症（HLP）患者进行三个月的氯倍他酯治疗（每日一次，每次100毫克）后，发现IIa型患者的总胆固醇浓度显著下降12.9%，IIb型下降23.7%，IV型下降20.8%。IIa型患者的低密度脂蛋白胆固醇浓度下降15.4%，IIb型下降8.3%，IV型患者的低密度脂蛋白胆固醇浓度有不显著的升高，升幅为21.6%。IIa型患者的初始甘油三酯水平下降36.1%，IIb型下降41.2%，IV型下降56.6%。在所有检测的HLP类型中，高密度脂蛋白胆固醇浓度均升高，IIa型升高19.5%，IIb型升高19.3%，IV型升高14.5%。在所有检测的HLP类型中，初始载脂蛋白A1和A2水平也有所升高，IIa型分别升高21.2%和12.4%，IIb型分别升高25.1%和11.0%，IV型分别升高23.6%和34.9%。IIa型患者的血清载脂蛋白B浓度显著下降20.5%，IIb型下降28.4%，然而IV型患者的载脂蛋白B水平略有升高。比较不同HLP类型对氯倍他酯治疗的反应发现，所检测的HLP类型在治疗后低密度脂蛋白胆固醇浓度、甘油三酯浓度和载脂蛋白B浓度的变化幅度上存在显著差异。
